Intra-nasal Ketamine for Analgesia in the Emergency Department

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-10-31

Study Completion Date

2013-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The provision of analgesia to patients in pain is a fundamental necessity of emergency department practice and is usually accomplished using IV opioids. However, significant barriers exist to the provision of timely analgesia by the IV route.

The use of the IN route for medication delivery provides an efficient and relatively painless mode of analgesia delivery. As well, ketamine is well-known to be an effective analgesic and to preserve cardiorespiratory function thus removing the necessity of physiologic monitoring that is obligatory when using opioids. The use of ketamine by the IN route provides a rapid, easy-administered and well-tolerated method for providing analgesia in the ED setting.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prehospital Analgesia With Intra-Nasal Ketamine

NCT02753114

Pain Acute Pain

COMPLETED PHASE4

Pain Free Laceration Repairs Using Intra-nasal Ketamine

NCT03053947

Laceration

COMPLETED PHASE2

Ketamine for Pain in the Emergency Department

NCT03896230

Acute Pain

TERMINATED PHASE4

Ketamine as a Supplement to Local Anesthesia for Minor Procedures

NCT06284473

Pain, Procedural Minor Laceration Abscess

RECRUITING PHASE4

Ketamine Versus Etomidate for Rapid Sequence Intubation

NCT01823328

Airway Control Anesthesia Intubation +1 more

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intra-nasal ketamine

0.5 mg/kg ketamine intra-nasally; then 0.25 mg/kg repeat dose after 10 minutes if necessary

Group Type EXPERIMENTAL

Intra-nasal ketamine

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intra-nasal ketamine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age 6 years or greater
* moderate or severe pain (VAS \>=50mm)

Exclusion Criteria

* history of allergy or intolerance to ketamine
* structural or functional nasal occlusion
* inability to understand the VAS
* Glasgow Coma Scale \< 15
* Systolic BP \> 180
* History of schizophrenia
* Clinical necessity for immediate IV access as judged by the treating physician

Minimum Eligible Age

6 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Gary Andolfatto

Assistant Professor, University of British Columbia Department of Emergency Medicine; Attending Physician and Emergency Department Research Director, Lions Gate Hospital

Responsibility Role PRINCIPAL_INVESTIGATOR